In April 2025， Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis was published online in
Gastroenterology. These recommendations address the areas with significant divergence， such as metabolic dysfunction-associated steatotic liver disease （MASLD） screening steps， the use of noninvasive tests for risk stratification， management of comorbidities， and the recent advances in resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis （MASH）， covering the most debated topics in current MASLD management. This article makes an excerpt of the main contents in these consensus recommendations.
DownLoad:
